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 COMMONWEALTH OF MASSACHUSETTS 
BOARD OF REGISTRATION IN PHARMACY 
 
MINUTES OF THE REGULARLY SCHEDULED MEETING 
239 Causeway Street, Fourth Floor Room 417A 
Boston, MA 02114 
 
Tuesday, March 3, 2015 
 
 
Board Members Present     Board Member Not Present 
Patrick Gannon, RPh, Present (arrives @ 9:02AM)  Garrett Cavanaugh, RPh. 
Edmund Taglieri Jr., RPh, President-elect   William Cox, CPhT 
Richard Tinsley, MBA, MEd, Secretary 
Catherine Basile, PharmD, RPh 
K. Conley, DNP, RN, AOCN, NEA-BC 
Susan Cornacchio, JD, RN 
Timothy Fensky, RPh, FACA 
Michael Godek, RPh 
 
Board Staff Present 
James Lavery, JD, Director, Health Professions Licensure 
David Sencabaugh, RPh, Executive Director 
David Dunn, RPh, Assistant Executive Director 
Heather Engman, JD, MPH, Board Counsel 
Kelly Ann Barnes, RPh, JD, Director of Pharmacy Quality Assurance 
William Frisch Jr., RPh, Director of Pharmacy Compliance 
Samuel Penta, RPh, Senior Pharmacy Investigator 
Christina Mogni, RPh, Pharmacy Investigator 
Monica Vasquez, Compliance Office 
Colleen Collins, RPh, Contract Pharmacy Investigator 
Richard Harris, Program Analyst 
 
TOPIC I. 
 
CALL TO ORDER 
DISCUSSION: A quorum of the Board was present. President-elect E. TAGLIERI 
chaired the meeting and asked if anyone in the audience was recording the meeting; no 
one indicated that they were recording the meeting. President elect E.TAGLIERI, also 
announced that the Board was recording the meeting. 
ACTION: At 8:36 AM E.TAGLIERI, called the March 3, 2015, meeting of the Board of 
Registration in Pharmacy to order. Board member attendance was indicated by roll call: 
E. TAGLIERI; yes, R.TINSLEY; yes, C.BASILE; yes, K. CONLEY; yes, S. 
CORNACCHIO; yes, T FENSKY; yes; M GODEK; yes, P GANNON was not present at 
the time of roll call. 
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TOPIC II. 
 
APPROVAL OF AGENDA       Time 8:38AM 
DISCUSSION: D. SENCABAUGH asked that the Pharmacist Re-Entry Policy be 
removed from the Flex Session portion of the Agenda 
ACTION: Motion by R.TINSLEY, seconded by K. CONLEY, and voted unanimously to 
accept the agenda with the noted change. P. GANNON was not present for the discussion 
or vote of this matter. 
 
TOPIC III. 
APPROVAL OF MINUTES 
 
1. Draft, September 30, 2014, Regular Session Minutes 
DISCUSSION: None 
ACTION: Motion by R. Tinsley, seconded by T. FENKY, and voted unanimously to 
approve the September 30, 2014, Regular Session Minutes. C. BASILE, K. CONLEY, S. 
CORNACCHIO, M. GODEK, abstained from the vote. P. GANNON was not present for 
the discussion or vote on this matter. 
 
2. Draft, October 9, 2014, Regular Session Minutes 
DISCUSSION: None 
ACTION: Motion by R. Tinsley, seconded by T. FENKY, and voted unanimously to    
approve the September 30, 2014, Regular Session Minutes. C. BASILE, K. CONLEY, S. 
CORNACCHIO, M. GODEK, abstained from the vote on this matter. P. GANNON was 
not present for the discussion or vote on this matter. 
 
3. Draft, December 15, 2014, Regular Session Minutes 
DISCUSSION: None 
ACTION: Motion by C. BASILE, seconded by M. Godek, and voted unanimously to 
approve the December 15, 2014, Regular Session Minutes. S. CORNACCHIO, K. 
CONLEY, T. FENSKY abstained from the vote on this matter. P.GANNON was not 
present for the discussion or vote of this matter. 
 
TOPIC IV. 
REPORTS        TIME 8:42 AM 
 
Applications Approved Pursuant to Licensure Policy 13-01 
DISCUSSION: R HARRIS noted that during the past month there has been eleven (11) 
change of managers, and one (1) pharmacy closure. 
ACTION: So noted 
 P.GANNON was not present for the presentation of the report. 
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TOPIC: V. 
FLEX SESSION 
 
1. Introduction of Pharmacy Intern James Kidd. 
Was already completed during the call to order. 
 
2. March 24, 2015 evening meeting 
D. SENCABAUGH informed the Board that a regulations meeting has been scheduled 
for March 24, 2015 from 5:30 – 8:30 pm. The attendance of Board members is vital. 
 
3. March 27, 201 Advisory Committee meeting 
D. SENCAUGH informed the Board that the meeting would discuss the purpose and 
mechanics of the advisory committee and encouraged Board members to attend and meet 
the members of the Pharmacy Advisory Committee. 
 
4. Board member involvement in NABP 
D. SENCABAUGH encouraged Board members to become active with NABP, noting 
that a gap had been left with the departure of prior Board members who had represented 
the Massachusetts Board at the NABP. The services NABP provides to the Board were 
noted. 
 
5. Ratification of the Plan of Correction (POC) policy 13-02 
DISCUSSION: W. FRISCH explained Policy 13-02 and asked the Board for ratification. 
There was no further discussion.  
ACTION: Motion by T. FENSKY, seconded by K. CONLEY and voted unanimously to 
approve Policy 13-02 Plan of Correction. P GANNON was not present for the discussion 
or vote on this matter. 
 
6. Update on pharmacy practice inquiries to the Board 
K. BARNES explained the inquiry process and tracking tool and provided data regarding 
email inquiries received by Board staff from April through December of 2014. The Board 
was shown on the screen a break-down for the four hundred and Sixty four (464) 
responded to and review by K. BARNES and her APPE rotation students. K. BARNES 
acknowledged the work of Pharmacy Intern Emily Walker for her organization of the 
data and formation of the slide. K. BARNES indicated that practice inquiries process has 
proven to be beneficial for both the students and licensees, providing timely and 
consistent answers to licensees’ questions. K. BARNES indicated that she would 
continue the tracking program looking to incorporate a tracking of phone calls handled by 
Board Staff. 
 
7. Guidelines for pharmacist continuing education: Sterile & Non-Sterile Compounding 
K. BARNES presented the Board with a draft Policy Guidelines for Pharmacist 
Continuing Education Requirements: Sterile & Non-Sterile Compounding. The purpose 
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of the policy is clarify for pharmacist the educational requirements established by chapter 
159 of the Acts of 2014. The Board discussed which pharmacists should be considered 
“engaged in” compounding, which Continuing Education (CE) would meet the 
requirement for compounding, and how compounding CEs would be monitored. It was 
agreed that the term “engaged in” in the statute is vague and it is necessary to include a 
definition in the regulations along with legislative intent. The guidelines were not acted 
on and would be brought back to the Board at a future meeting 
 
 
BREAK   9:35-9:47 
 
 
TOPIC VI. 
APPLICATIONS 
 
VI. APPLICATIONS 
1. Application for Licensure as a Wholesale Distributor    9:48 AM   
Rotem, Inc. 461 Boston Road, Unit 4D Topsfield, MA 
DISCUSSION: Peter Foti, Director of US Operations, and Kathy Ceifert, Director of 
Regulatory Affairs, presented this application.  Rotem, Inc. is seeking licensure as a 
limited service wholesale distributor of sodium chloride and sterile water for injection, to 
manufacturers and nuclear pharmacies. 
 
Currently, Rotem plans only to carry C-VI drugs, but they were asked to submit 
information to the Board if, and when, that should change. 
 
ACTION:  Motion by R. TINSLEY, seconded by E. TAGLIERI, and voted unanimously 
to approve the application, pending a successful inspection.  
________________________________________________________________________ 
TOPIC: 
VI. APPLICATIONS  
2. Application for Transfer of Ownership of a Community Pharmacy  
Crawford Drug, LLC. 1735 Dorchester Ave, Dorchester, MA 
DISCUSSION: AED David Dunn reported to the Board that Crawford Drug LLC has 
submitted a transfer of ownership request.  Owner / MOR Norman Kinan has transferred 
ownership to his son MOR Steven Kinan and grandson Michael Wilson, RPh.  There will 
be no changes to the name of the facility or policies and procedures of Crawford Drug. 
  
ACTION: Motion by C. BASILE, seconded by, M. GODEK, and voted unanimously, to take 
approve the transfer of ownership conditioned on a successful re-inspection. 
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TOPIC: 
VI. Applications        9:59AM 
Review of Application for renovation / expansion and review of request to initiate 
sterile compounding 
Boulevard Compounding Center, 149 Shrewsbury Street, Worcester, MA 
 
Joseph Rossetti, Owner / MOR presented the case for Boulevard Compounding Center, to 
perform sterile compounding.  Although they had done sterile compounding in the past, 
they have not done so since the full scale inspection of sterile compounders back in late 
2012 and early 2013.  They voluntarily ceased sterile compounding in approximately 
October 2012 and commenced plans to renovate their facility, so as to conform to USP 
797 guidelines before resuming sterile compounding. 
 
W. FRISCH presented and summarized a memorandum and timeline regarding 
Boulevard.  The timeline indicated  Mr. Rossetti and Mr. Gene Svirsky presented the 
renovation plans at the October 1, 2013 Board of Pharmacy Meeting.  The Board 
approved the plans for the renovation at that time, pending successful inspection.   
 
On June 27, 2014, Senior Investigators Penta and McKenna inspected Boulevard 
Compounding Center and found them sufficiently compliant for non-sterile (<795>) 
compounding, but the sterile component was not ready at that time.  Beginning sometime 
in September of 2014, OPP was contacted by a consultant for Boulevard (BLVD), to 
trigger the final approval process.  However, Director of Pharmacy Compliance, William 
Frisch, noted a number of outstanding issues, including  training of staff, formulation 
worksheet questions, environmental testing, BUD dating, and other items required to 
demonstrate the competency required for sterile compounding, particularly for high-risk 
sterile compounding, as was described in BLVD’s business model. 
 
Director Frisch made it clear that Mr. Rossetti and BLVD have been very cooperative in 
responding to requests, but that still, there were issues to resolve, including the training 
required for MOR Rossetti and RPh Arakelian. 
 
MOR Rossetti has been given a list of items to complete, and was asked by Board 
President Gannon if he understood what he needed to do in order to begin sterile 
compounding.  MOR. Rossetti responded in the affirmative, and it was made clear by the 
Board, that that he would still need final approval before commencing “high-risk” sterile 
compounding. 
 
ACTIONS: Motion by T. FENSKY, seconded by, M. GODEK, and voted to APPROVE 
initiation of  low and medium risk level sterile compounding, provided the following 
conditions are met: 
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1. Boulevard submits documentation satisfactory to Board staff 
demonstrating that pharmacists Joseph Rossetti and Geraldine 
Arakelian, and any technician that will engage in sterile 
compounding, underwent formal training regarding sterile 
compounding and United States Pharmacopeia General Chapter 
797 (“USP 797”).  The training must include, but should not be 
limited to, Aseptic Technique, Hand Hygiene and Garbing, and 
Cleaning and Disinfecting.   
 
2. Boulevard submits documentation satisfactory to Board staff 
demonstrating that pharmacists Joseph Rossetti and Geraldine 
Arakelian, and any technician that will engage in sterile 
compounding, successfully pass media fill tests and gloved 
fingertip/thumb sampling, in accordance with USP 797.  The 
media fill tests shall represent the most challenging conditions 
encountered during sterile compounding at the pharmacy.    
 
 
3. Boulevard submits documentation satisfactory to Board staff 
demonstrating that pharmacists Joseph Rossetti and Geraldine 
Arakelian, and any technician that will engage in sterile 
compounding, are successfully trained in the storage, handling, 
and disposal of hazardous drugs, in accordance with USP 797.    
 
4. Boulevard enters into an Agreement with the Board that 
requires Boulevard to refrain from all high risk level sterile 
compounding until the pharmacy: (a) validates the sterility, 
stability, and beyond use dates of its high risk level products in 
accordance with USP 797; (b) submits complete formulation 
worksheets; (c) submits documentation demonstrating that all 
personnel engaged in high risk level sterile compounding 
completed formal training in high risk level sterile compounding 
and media fill tests in accordance with USP 797; and (d) receives 
written approval from the Board to engage in high risk level 
sterile compounding.   
 
Boulevard may not engage in any low or medium risk level sterile 
compounding until the conditions described above are met and Boulevard 
receives written approval from the Board to begin low and medium risk level 
sterile compounding.   
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Final vote was YES by a majority vote of 5 in the affirmative and 3 in the negative.  
Board Members K. CONLEY, P. GANNON, and E. TAGLIERI opposed. 
________________________________________________________________________ 
TOPIC 
VI. APPLICATIONS 
Update Change in Business Model 
Soleo Health, 5 Shawmut Rd., Suite 103, Canton, MA 
DISCUSSION:  
The Board received a letter from MOR Smith regarding a change in the business model 
for Soleo Health. At the February 3, 2014, the approved Soleo Health’s application to 
operate a New Community Pharmacy pending receipt of waivers and a successful 
inspection. In her letter MOR Smith indicates that construction of the new facility has 
been delayed impacting the ability to service patients. MOR Smith indicates that Soleo 
Health desires to lease a space adjacent to the new pharmacy in order to provide patients 
with non-compounded product Immunoglobulin and Factor products.” 
ACTION: Motion by R. TINSLEY, seconded by K. CONLEY, and voted unanimously to 
approve the use of the temporary space, until such time as the permanent space has been 
completed, subject to successful inspection. The space can be used temporarily for six (6) 
months maximum.  Any additional time needed would have to be approved by the Board. 
________________________________________________________________________ 
TOPIC 
VII. FILE REVIEW 
 
1. SA-INV-4430, Gary Drug, DS3937     10:47 AM 
Investigation report Presented and Summarized by: M. VASQUEZ 
DISCUSSION: On July 5, 2013, the OPP was notified by the Florida Attorney General, 
that Greenfield Enterprises, Inc. DBA Gary Drug Company, had purchased 
pharmaceuticals from Countrywide Distributors, which was change with, “Trafficking in 
Contraband Prescription Drugs, Conspiracy to Traffic in Contraband Prescription Drugs, 
Organized Scheme to Defraud, and Money Laundering. OPP investigators inspected the 
facility in July of 2013 and found no evidence of purchases of pharmaceuticals from 
Countrywide Distributors by the licensee. H. ENGMAN added that the Florida Attorney 
Generals office was also unable to provide evidence of purchases by the Gary Drug. 
 
Action: Motion by M. GODEK, seconded by C. BASILE, and voted unanimously to 
close the Staff Assignment SA-INV-4430 due to insufficient evidence. 
 
2. SA-INV-5084, CutisPharma, Inc. WD466, 
Investigation report Presented and summarized by: M.VASQUEZ 
DISCUSSION: Staff Assignment was opened in response to concerns that convenience 
compounding kits manufactured by CutisPharma were not in compliance with USP 
<795>.  On April 11, 2014, OPP investigators conducted a relocation compliance 
inspection and found no deficiencies of Board regulations. W. FRISCH offered that the 
Cutis Pharma, Inc., is a manufacturer, possessing both FDA and Drug Control Program 
licensure. W. FRISCH noted that it is not necessary to have both a DCP and Board 
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wholesale distributor license.  The Board of Pharmacy Wholesale Distributor license 
subsequently expired. 
 
ACTION: Motion by T. FENSKY, seconded by C.BASILE, and voted unanimously to 
close Staff Assignment SA-INV-5084 with no violation. 
 
3. SA-INV-5082, Medicine Shoppe,    DS89894 
Investigation report Presented and summarized by: C. MOGNI 
DISCUSSION:  The OPP was notified by the Drug Control Program, that during an 
inspection of a clinic it was found that the Medicine Shoppe had provided Massachusetts 
controlled substance to the clinic without a valid prescription. A routine compliance 
inspection was conducted in March 2014. MOR Patel purchase the Medicine Shoppe in 
November of 2013. A review of the records, during a March 2013 compliance inspection 
indicated that the process of supplying the clinic with medication took place from March 
of 2012 thru September of 2013 under the previous owner. The compliance inspection 
yielded multiple deficiencies which were addressed by MOR Patel via a plan of 
Correction. The Medicine Shoppe was inspected for routine compliance in April 2014 
and was deemed to be satisfactory. 
  
ACTION : Motion by C. BASILE seconded by K. Conley, and voted unanimously to 
close Staff Assignment SA-INV-5082 , discipline not warranted because process of 
supplying clinic with medication occurred prior to the involvement of current 
owner/MOR. 
 
4. PHA-2014-0212; Richard Tilton,   PH14138  10:49AM 
Investigation report Presented and Summarized by C. MOGNI 
DISCUSSION: Pharmacist Tilton was the former Owner/ MOR of the Prescription 
Shoppe in Beverly. In response to the companion complaint Pharmacist Tilton admitted 
to supplying Massachusetts controlled substances ( antivirals and antibiotics) to a clinic 
for dispensing to patients, in violation of 247 CMR 7.02 (1).  
 
ACTION: Motion by Taglieri, seconded by T.FENSKY, and voted unanimously to refer 
the matter to the Office of Prosecution for the issuance of an Order to Show Cause 
authorizing resolution of this matter with a Consent Agreement  for non disciplinary 
stayed probation with terms to include, five (5) contact hours of continuing education and 
an attestation that the registrant has read and review M.G.L c. 94-C. 
 
5. SA-INV-5112, Walgreens 15390,      10:58AM 
Investigation report Presented by Christina Mogni 
Recusal: Michael Godek recused himself and was not present for the discussion or vote 
on this mater.   
DISCUSSION: The Board discussed the nature of the complaint against the Walgreens 
Well Experience model regarding confidential patient information and mentioned 
concerns about controlled substances security. The complaint was dismissed because it 
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was about the model itself and not about specific deficiencies at the drug store in 
question, which showed no evidence or concern of unauthorized PHI disclosure. 
ACTION: Motion by E. TAGLIERI, seconded by C. BASILE, and voted unanimously to  
Close Staff Assignment  SA-INV-5112 with no violation 
 
 
 
6. SA-INV-5202, The Whittier Pharmacist, DS3587  11:01AM 
    Investigation report Presented and summarized by Colleen Collins 
    RECUSAL:  Board Member Ed Taglieri recused himself from this discussion and vote. 
DISCUSSION: On 12/20/2013, The Office of Public Protection received a mandatory 
self-report of a Disclosure of Abnormal Results from The Whittier Pharmacist.  
Specifically, it was reported that on November 14, 2013, one air impaction sample 
obtained in one pharmacy barrier isolator, had exceeded the recommended quantity for 
colony forming units (CFU’s) as recommended by USP 797.  
 
According to MOR Luciano, The Whittier Pharmacist did not use PEC1 per protocol 
when notified of the Abnormal Result from B & V Testing and that PEC1 was not 
used from 12/3/13 until 1/9/14, when preliminary reports came back showing no 
growth. 
 
On 3/9/14, was inspected for <797> Compliance by the OPP, and was assessed as 
satisfactory.  On April 30, 2014, the OPP received the Plan of Correction, which 
indicated that 10 specific corrective measures had been implemented. 
ACTION: Motion by R.TINSLEY, seconded by T. FENSKY and voted unanimously 
to close the Staff Assignment with discipline not warranted. 
 
7. PHA-2014-0097, Home Solutions, DS89639    11:04AM 
          Investigation report Presented and Summarized by: C. MOGNI 
          DISCUSSION: Pharmacy failed to conduct viable air sampling after cleanroom    
          modifications in violation of USP<797>, discovered upon inspection.  Pharmacy  
          voluntarily closed and conducted proper environmental monitoring and had  
          successful inspection prior to re-opening.   
  
MOR Norcross voluntarily ceased compounding and initiated remediation efforts. 
POC submitted included retraining on recertification requirements and viable 
sand non-viable environmental monitoring. W.Frisch noted: Pharmacy has 
recently undergone a major overhaul to HVAC and other physical plant 
improvements.  
Board staff noted remediation and POC were sufficient, no further remediation is 
necessary and recommended the complaint be closed discipline not warranted. 
ACTION: Motion by C. BASILE, seconded by E.TAGLIERI, and voted 
unanimously to dismiss complaint PHA-2014-0097, with discipline not 
warranted. 
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TOPIC VIII. 
REGULATIONS      Time:11:08 AM- 12:35PM 
1. Proposed amendments to 247 CMR 9.00 Code of Professional Conduct; Professional 
Standards for Registered Pharmacists, Pharmacies, and Pharmacy Departments. 
DISCUSSION: The draft proposed regulation was displayed on screen for Board 
members and the audience to view. Board Counsel H. ENGMAN captured Board 
members concerns and changes to the Draft document via track changes on screen for 
Board members and the audience to view.  
 
LUNCH BREAK  12:35PM – 1:35PM 
 
TOPIC IX.  
Executive Session (M.G.L. c. 30A, §21(a))   TIME: 1:36PM 
DISCUSSION: P. GANNON noted that the Board would not return to open session 
following closed session 
ACTION: Motion by E. TAGLIERI, seconded by C. BASILE, and voted unanimously by 
roll call to enter into Executive Session. P.GANNON; yes, E. TAGLIERI; yes, 
R.TINSLEY; yes, C. BASILE; yes, K. CONLEY; yes, S.CORNACCHIO; yes, 
T.FENSKY; yes, M.GODEK; yes. 
 
TOPIC X. 
M.G.L c. 112§ 65C SESSION      TIME: 1:54PM 
DISCUSSION: None 
ACTION: Motion by T.FENSKY , seconded by M.GODEK, and voted unanimously to 
enter into M.G.L. c. 112 65C Session. 
 
TOPIC XI. 
ADJOURN MEETING      TIME: 4:45PM 
DISCUSSION: NONE 
ACTION: Motion by, E.TAGLIERI, seconded by T. FENSKY, and voted unanimously 
to adjourn the meeting 
 
 
Respectfully submitted,  
 
 
Richard J. Tinsley, MBA, M.Ed. 
Secretary 
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LIST OF EXHIBITS USED DURING THE GENERAL SESSION 
 
1.  Preliminary Agenda for the March 3, 2015, Scheduled Meeting 
2.  Draft Regular Session Minutes, September 30, 2014 Meeting 
3.  Draft Regular Session Minutes, October 9, 2014 Meeting 
4.  Draft Regular Session Minutes, December 15, 2014 Meeting 
5.  Application Wholesale Distributor, Rotem Inc. 
6.  Notice of Transfer of Ownership, Crawford Drug 
7.  Application for Renovation / Expansion and request to initiate sterile 
compounding-    Boulevard Pharmacy 
8.  Soleo Health, Inc. letter 
9.  Report licenses approved pursuant to Licensure Policy 13-01 
10.  Draft Guidelines for pharmacist Continuing Education : Sterile and Non-Sterile 
Compounding 
11.  Plan of Correction Policy 13-02 
12. Investigative report in the matter of Gray Drug; DS3937, SA-INV-4430 
13.  Investigative report in the matter of Cutis Pharma; WD466, SA-INV-5084 
14. Investigative report in the matter of The Medicine Shoppe 500; DS89894,  
SA-INV-5082 
15. Investigative report in the matter of Richard Tilton; PH14138, PHA-2014-0212 
16. Investigative report in the matter of Walgreens 15390; DS89867, SA-INV-5112 
17. Investigative report in the matter of The Whittier Pharmacist; DS3587,  
SA-INV-5202 
18. Investigative report in the matter of Home Solutions; DS89639, PHA-2014-0097 
19. Proposed Regulations 247 CMR 9:00: Code of Professional Conduct; 
Professional Standards for Registered Pharmacists, Pharmacies and Pharmacy 
Departments. 
20. Proposed Regulations 247 CMR 9:00 Code of Professional Conduct: Professional 
Standards for Registered Pharmacists, Pharmacies and Pharmacy Departments 
with track changes. 
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